U.S. Retail REITs Stock News

NYSE:AGL
NYSE:AGLHealthcare

agilon health (AGL) Stock May Be Below Fair Value On Raised Guidance

Agilon health stock has had a very strong year so far, yet the valuation checks still point to shares screening cheap on several measures. For investors looking at agilon health today, the combination of a sharp year to date gain and a high value score raises questions about how much upside, if any, is already reflected in the price. Year to date, agilon health is up about 459%, which is an unusually large move that can leave the stock more sensitive to shifts in expectations. Recent news...
NYSE:CNH
NYSE:CNHMachinery

CNH Industrial (CNH) Stock Trades Near Fair Value After 22% Gain

CNH Industrial stock has delivered a 22.2% gain year to date, yet broader valuation checks suggest the shares are not an obvious bargain and trade close to what many would consider a fair range. The 22.2% year to date return signals improving sentiment toward CNH Industrial, even though the stock remains down over the past year and across longer multi year periods. Planned investment of ₹2,000 crore in India to expand tractor manufacturing capacity may support future earnings power. However,...
NYSE:CHWY
NYSE:CHWYSpecialty Retail

Should Chewy’s Vet Clinic Push and Autoship Dependence Reshape Long-Term Cash Flows for CHWY Investors?

Chewy has recently come back into focus ahead of its now-completed September 9, 2026 fiscal second-quarter earnings report, with investors weighing its expansion into Chewy Vet Care Clinics and continued dependence on Autoship subscriptions. The tension between Chewy’s relatively high valuation multiples and its push into the multi-billion-dollar veterinary services market has become central to how investors assess its long-term cash-flow potential and execution risk. We’ll now explore how...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

Could AeroVironment (AVAV) Be 33% Undervalued As NASA Mars Helicopter Deal Lands?

AeroVironment (AVAV) has attracted fresh attention after its MacCready Works team secured a NASA contract to co-design and co-manufacture three Mars helicopters for the SkyFall mission, which is planned for launch in late 2028. Despite the NASA SkyFall contract and recent defense orders, AeroVironment’s share price has come under pressure, with a year to date share price return down 40.6% and a 1 year total shareholder return down 38.8%, even though the 3 year total shareholder return is...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?

Madrigal Pharmaceuticals has delivered very strong long term share price gains, yet the current valuation checks still lean toward the stock looking cheap on the broader scorecard. That combination raises questions for investors trying to judge whether recent trading levels already reflect the progress in the business. Over the past 5 years, Madrigal Pharmaceuticals has produced a very large total return, which puts extra focus on whether today’s price still leaves room for further value...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Eli Lilly (NYSE: LLY) received FDA approval for Mounjaro to reduce major cardiovascular risk in adults with type 2 diabetes who are at high risk. The new indication expands Mounjaro’s approved use beyond blood sugar control to include cardiovascular risk reduction. The decision could influence how clinicians position Mounjaro in care plans for adults with type 2 diabetes and elevated cardiovascular risk. Payers may factor the cardiovascular indication into future coverage and reimbursement...
NasdaqGS:AAPL
NasdaqGS:AAPLTech

Apple (AAPL), Why Is The Latest Update Drawing So Much Attention?

Apple (AAPL) has pushed its AI hardware story forward with the launch of M6 and M5 Ultra chips in new Mac mini and Mac Studio models, sharpening investor focus on on-device AI capabilities. Apple’s share price has moved around this year, with a 1-day share price return of 0.36% and a 7-day share price return of 1.05%, while the 30-day share price return is down 7.5% after a strong year-to-date gain of 16.08%. Over longer periods, total shareholder return shows solid wealth creation, with a...
NasdaqGS:META
NasdaqGS:METAInteractive Media and Services

Meta Platforms (META) Settles Youth Safety Claims, Is The Valuation Gap Too Wide?

Meta Platforms (META) just agreed to pay up to US$18b over ten years to settle youth safety claims, while also locking in stricter teen time limits and new content controls across Facebook and Instagram. Despite the settlement, Meta Platforms’ recent share price performance has been mixed, with a 7 day share price return of 4.63% but a year to date share price decline of 12.19%. The 3 year total shareholder return of 94.71% contrasts with a 1 year total shareholder return decline of 23.72%,...
NasdaqGS:DIOD
NasdaqGS:DIODSemiconductor

Does Diodes (DIOD) Look Reasonable After The ElevATE Deal?

Diodes stock has logged a strong run so far this year, yet the broader valuation checks suggest the shares no longer look like a clear bargain. With the stock already up sharply, investors are weighing how much of the recent optimism is already reflected in the current price. Year to date the stock has returned 76.7%, which raises the bar for any further gains to be supported by fundamentals rather than momentum alone. The completed acquisition of ElevATE Semiconductor may support...
NYSE:WES
NYSE:WESOil and Gas

Is Western Midstream Partners (WES) Fully Valued After Its Solitude Pipeline Joint Venture?

Western Midstream Partners (WES) is drawing attention after joining the Solitude Pipeline System joint venture. The venture has approved construction of two long-haul natural gas pipelines from the Permian Basin to Katy, Texas. For context, Western Midstream Partners’ share price has eased slightly in the past week, with a 7 day share price return of 1.73% and a 1 day move lower, even as the 90 day share price return of 11.52% and year to date gain of 20.37% point to building momentum. The 1...
NasdaqGS:ADP
NasdaqGS:ADPProfessional Services

Can Automatic Data Processing (ADP) Justify Its Price On AI And Hiring Momentum?

Automatic Data Processing (ADP) stock drew fresh attention after the company reported consecutive weekly increases in U.S. private-sector job additions and highlighted ongoing investments in AI-driven automation and global human capital management platforms. The recent updates on U.S. private-sector job additions and ADP’s AI-focused HCM investments arrive as the stock trades at US$284.68, with a 30-day share price return of 7.76% and a 90-day share price return of 28.33%, while the 1-year...
NYSE:BBY
NYSE:BBYSpecialty Retail

Best Buy (BBY) Raises Full Year Guidance As Ad Network Sales Near $1 Billion

Best Buy (NYSE: BBY) raised its full-year sales and profit guidance following stronger than expected second quarter results. The company highlighted rapid growth in its retail media business and expects ad network sales to approach US$1b in 2026. Management pointed to the ad network as an important source of diversified revenue beyond traditional electronics retail. To broaden your view across related opportunities in technology and retail, explore 55 AI infrastructure stocks. NYSE:BBY...
OTCPK:LKNC.Y
OTCPK:LKNC.YHospitality

Luckin Coffee (OTCPK:LKNC.Y) Dropped, So What Is Driving Attention Now?

Fresh interest in Luckin Coffee (OTCPK:LKNC.Y) has been triggered by recent analyst coverage highlighting higher earnings estimates and a top Zacks Rank. This has drawn attention to how the stock’s current pricing compares with those expectations. Over the past month Luckin Coffee has delivered a 30 day share price return of about 10%, although the share price has eased in the last week and is now at US$35.25. The 1 year total shareholder return is slightly negative and the 5 year total...
NasdaqGM:CRVS
NasdaqGM:CRVSBiotechs

Does Peer-Reviewed Phase 1 Soquelitinib Data Reshape The Bull Case For Corvus Pharmaceuticals (CRVS)?

Corvus Pharmaceuticals recently reported in Blood the final peer-reviewed Phase 1/1b data for its oral ITK inhibitor soquelitinib in advanced T cell lymphomas, showing durable responses, a median overall survival exceeding two years, and a favorable safety profile across multiple dose levels. The publication strengthens the scientific case for soquelitinib’s selective ITK inhibition and Th1-skewing mechanism, underpinning Corvus’s ongoing registration Phase 3 PTCL trial and broader...
NasdaqGS:NOVT
NasdaqGS:NOVTElectronic

Novanta (NOVT) Could Be 26% Below Fair Value On Strong Quarterly Results

Why Novanta’s strong quarter matters for shareholders now Novanta (NOVT) posted quarterly revenue that exceeded analyst expectations and issued EBITDA and revenue guidance above forecasts. Yet the stock has slipped since the report, which hints that investor expectations were already high. Over the past year, Novanta’s share price has moved sharply higher, with a year-to-date share price return of 30.15% and a 1-year total shareholder return of 22.51%. However, the 9.21% share price decline...
NYSE:LDOS
NYSE:LDOSProfessional Services

Is New AI Army Cyber Deal Reshaping The Investment Case For Leidos Holdings (LDOS)?

In recent days, Leidos Holdings, Inc. announced two new U.S. defense health and cyber contracts: a US$301,000,000, five-year Army network monitoring agreement and a US$56,000,000, 66‑month Naval Health Research Center award for behavioral health research and operational assessments. Together, these wins highlight how Leidos is tying advanced AI-enabled cyber defense with data-driven psychological health work, deepening its role in supporting military readiness across both digital and human...
NYSE:ECG
NYSE:ECGConstruction

How Rising Analyst Earnings Estimates At Everus Construction Group (ECG) Have Changed Its Investment Story

In recent days, analysts have revised their earnings estimates higher for Everus Construction Group, Inc. (NYSE: ECG), reflecting increased optimism about the company’s earnings outlook. This broad-based shift in expectations, paired with a top-tier Zacks Rank #1 (Strong Buy), suggests analysts see its earnings power differently than before. With analysts increasingly aligned in raising earnings estimates, we’ll now examine how this improved sentiment interacts with Everus Construction...
NYSE:VLO
NYSE:VLOOil and Gas

Valero Energy (VLO) Earnings Beat Raises The Question Of Whether The Stock Is Already Priced In

Valero Energy (VLO) attracted fresh attention after its second quarter 2026 results showed a large improvement in adjusted earnings per share and revenues, along with a top Zacks Rank based on expected earnings growth. Against this backdrop, Valero Energy’s share price has climbed to $346.59, supported by a 30 day share price return of 15.96% and a 90 day share price return of 41.57%. The 1 year total shareholder return of 134.15% shows how strong the recent momentum has been despite a small...
NasdaqGS:WDAY
NasdaqGS:WDAYSoftware

What Is Workday (WDAY) Gaining From Its New Compensation Data Integration?

Workday (NasdaqGS: WDAY) and Salary.com announced a certified integration that automates compensation data management for joint customers. The integration connects Workday Human Capital Management with Salary.com to synchronize job, employee, and pay data for compensation teams. Customers gain a direct link between internal compensation management and external market pricing data to support pay decisions. Early adoption from financial services firms highlights immediate interest from sectors...
NYSE:CHE
NYSE:CHEHealthcare

Chemed (CHE) Dropped, What Is Behind The Fresh Attention?

Chemed stock performance snapshot after recent price moves Chemed (CHE) has drawn fresh attention after recent price moves, with the stock last closing at US$520.27. That level reflects mixed short term returns and a stronger picture over the past 3 months. Over the past year Chemed has delivered a 15.74% total shareholder return. The recent 1 day share price move down 5.16% to US$520.27 contrasts with a 22.01% 90 day share price return, suggesting momentum has cooled slightly after a strong...
NasdaqCM:CELH
NasdaqCM:CELHBeverage

How Investors May Respond To Celsius Holdings (CELH) Analyst Downgrades And Extended Recovery Timeline

Recently, Celsius Holdings reported weaker-than-expected second-quarter earnings, prompting several brokerages including Deutsche Bank, Bernstein, and Maxim to downgrade the energy drink maker due to concerns over softer core brand trends and a longer recovery timeline into fiscal 2027. This clash between cautious analyst revisions and earlier optimism about Celsius’ growth and profitability potential highlights how sensitive the company’s valuation is to shifts in earnings...
NasdaqGS:SHOP
NasdaqGS:SHOPIT

Is Shopify (SHOP) Above Fair Value, Or Already Priced For Perfection?

Shopify stock has delivered a strong 3 year return, yet several valuation checks now suggest the shares trade at a premium to what the company’s current cash flow profile and fundamentals may justify. Both a Discounted Cash Flow (DCF) intrinsic value estimate and market multiple comparisons point in the same direction, which puts the recent share price strength under the spotlight for investors. Over the past 3 years, Shopify has returned about 132.1% which puts extra focus on whether...
NYSE:BEN
NYSE:BENCapital Markets

Does Franklin Templeton’s Tokenized Fund Push in Asia Reshape Its Long-Term Strategy Narrative (BEN)?

Franklin Templeton recently paid a quarterly cash dividend of US$0.33 per share on October 9, 2026, to shareholders of record on September 30, 2026, matching the prior quarter’s payout and reflecting a 3.1% increase over the same quarter a year earlier. Separately, HashKey Holdings Limited announced a collaboration under which HashKey Exchange will distribute Franklin Templeton’s tokenized Franklin OnChain U.S. Government Liquidity Fund (grBENJI) to eligible digital asset investors in Asia,...
NYSE:VMC
NYSE:VMCBasic Materials

Vulcan Materials (VMC) Stock Looks Fully Valued At Current Levels

Vulcan Materials has delivered a solid 55.7% total return over the past 5 years, yet current valuation checks suggest the stock is trading at a premium to its estimated intrinsic value. Both cash flow based and market multiple assessments currently point to Vulcan Materials looking expensive rather than like an obvious bargain. The 55.7% gain over 5 years indicates that long-term holders have already captured a significant portion of the value on offer from Vulcan Materials. Future pricing...